Selective Serotonin Reuptake Inhibitors as First-Line Antidepressant Therapy for Perinatal Depression

2017 ◽  
Vol 62 (3) ◽  
pp. 317-328 ◽  
Author(s):  
Gwen Latendresse ◽  
Christina Elmore ◽  
Ann Deneris
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Perinatal Depression ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin ◽  
First Line

Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors

2005 ◽  
Vol 66 (08) ◽  
pp. 974-981 ◽  
Author(s):  
Michael E. Thase ◽  
Barbara R. Haight ◽  
Nathalie Richard ◽  
Carol B. Rockett ◽  
Melinda Mitton ◽  
...  
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin ◽  
Remission Rates

scholarly journals FARMAKOTERAPI GANGGUAN ANSIETAS DAN PENGARUH JENIS KELAMIN TERHADAP EFIKASI ANTIANSIETAS

2020 ◽  
Vol 8 (1) ◽  
pp. 96-103
Author(s):  
Fatimah Azzahra ◽  
Rasmi Zakiah Oktarlina ◽  
High Boy Karumulborg Hutasoit
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Clinical Manifestations ◽  
Signs And Symptoms ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
First Line ◽  
General Signs ◽  
Keywords Anxiety ◽  
Global Population

ABSTRAK Ansietas merupakan perasaan difus, yang sangat tidak menyenangkan dan tidak menentu tentang sesuatu yang akan terjadi. Menurut WHO, jumlah populasi global yang menderita ansietas pada tahun 2017 diperkirakan mencapai 3.8%. Estimasi total dari jumlah individu yang menderita ansietas di dunia adalah 284 juta orang. Hal ini menunjukkan peningkatan yang cukup tinggi dari tahun 2005 yakni sekitar 15.1%. Manifestasi klinis dari ansietas berbeda tergantung pada bentuk gangguannya, tetapi tanda dan gejala umum dari ansietas memeiliki karakteristik yang terdiri dari dua komponen yaitu fisik dan emosional yang memengaruhi proses kognitif seseorang. Pengobatan ansietas dapat menggunakan obat – obatan antiansietas, psikoterapi, ataupun keduanya. Lini pertama dari farmakoterapi ansietas adalah Selective Serotonin Reuptake Inhibitors (SSRIs) yang biasanya digunakan sebagai antidepresi. SSRIs dipilih sebagai lini pertama karena memiliki efek samping yang lebih rendah dibandingkan obat golongan lainnya. Terdapat pengaruh jenis kelamin terhadap efikasi antiansietas yang berguna terhadap pemilihan antiansietas.  Kata Kunci : Ansietas, Antiansietas, Farmakoterapi, Pengobatan   ABSTRACT Anxiety is a diffuse feeling, which is very unpleasant and uncertain about something that will happen. According to WHO, the total global population suffering from anxiety in 2017 is estimated to reach 3.8%. The total estimated number of people living with anxiety in the world is 284 million people. This shows a fairly high increase from 2005 which was around 15.1%. Clinical manifestations of anxiety is different depending on the form of the disorder, but the general signs and symptoms of anxiety have characteristics that consist of two components, that is physical and emotional that affect someone cognitive processes. The treatment of anxiety can using drugs, psychotherapy, or both. The first line of pharmacotherapy for anxiety is Selective Serotonin Reuptake Inhibitors (SSRIs), which are usually used as antidepressants. SSRIs were chosen as first-line because they have lower side effects than other class of drugs. There is an effect of sex on the efficacy of antianxiety that is useful for selection of the antianxiety.  Keywords : Anxiety, Antianxiety, Pharmacotherapy, Treatment

scholarly journals Paroxetine induced bruxism, treated with Buspirone : An unexplored entity

2014 ◽  
pp. 29-31
Author(s):  
Seshadri Sekhar Chatterjee ◽  
Arnab Maji ◽  
Nitu Mallik
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Side Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Sleep Problems ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
First Line ◽  
The Central Nervous System

SSRI are the widely prescribed first line drugs for depression and as depression very commonly presents with insomnia SSRI are good at improving the sleep problems also. But though rare the occurrence of sleep related side effects like bruxism,it may cause significant distress and cause of nonadherence which easily may be overlooked. In this case we report a case of Paroxetine induced bruxism and subsequently treated with withdrawing the drug and buspirone. Though the aetiology of such bruxism remained unclear, the imbalances in dopaminergic and serotonergic activities in the central nervous system is mostly implicated.Key Words : Bruxism, Escitalopram, Parafunctional activity, Selective Serotonin Reuptake Inhibitors

scholarly journals Antidepressants in the Practice of a Gastroenterologist

2021 ◽  
Vol 17 (4) ◽  
pp. 90-93
Author(s):  
L.D. Firsova ◽  
Keyword(s):  
Side Effects ◽  
Serotonin Reuptake ◽  
Digestive System ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Tricyclic Antidepressants ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin ◽  
Therapeutic Effects ◽  
Cardiovascular Pathology

Antidepressants are widely used in modern gastroenterology. The article discusses the indications for the prescribing antidepressants to the patients with disorders of the digestive system, examines the features of antidepressant therapy in the gastroenterological patients with comorbid cardiovascular pathology. The main groups of antidepressants (selective serotonin reuptake inhibitors and tricyclic antidepressants) are compared in terms of therapeutic effects and potential side effects

Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics

1998 ◽  
Vol 12 (4_suppl) ◽  
pp. 55-S87 ◽  
Author(s):  
Burton J. Goldstein ◽  
Paul J Goodnick
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Safety Margin ◽  
Antidepressant Drugs ◽  
Healthcare Services ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin

The clinical use of tricyclic antidepressants (TCAs) is often complicated by toxicity and safety problems due to their effects on multiple mechanisms of action, many of which are unnecessary for therapeutic effect. The development of the selective serotonin reuptake inhibitors (SSRIs), with their selective mode of action, has resulted in a class of antidepressant drugs possessing an improved side-effect profile, while retaining good clinical efficacy. Their introduction into clinical practice has led to enhanced patient compliance with antidepressant therapy and the ability to maintain treatment over longer periods of time at an adequate therapeutic dose. Although, as a result of their selective action, side-effects associated with SSRI therapy are minimised, distinct variations between individual SSRIs in terms of their tolerability profiles have been observed. The wealth of clinical data now available has revealed differences in their potential to cause psychiatric and neurological side-effects, dermatological reactions, anticholinergic side-effects, changes in body weight, sexual dysfunction, cognitive impairment, discontinuation reactions and drug-drug interactions. Patients who suffer from concomitant depression and physical illness may experience different tolerability profiles, in addition to the greater likelihood that they will be receiving concomitant medications with the potential for pharmacokinetic drug-drug interactions with coadministered SSRI therapy. In addition, the safety margin of SSRIs in overdose may vary within the group. Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients. A successful clinical outcome leads to a reduced economic burden for the patient, their family and the healthcare services. Thus, pharmacoeconomic considerations are also important in choosing antidepressant therapy. The SSRIs, despite relatively higher prescription costs, have been demonstrated to be a more cost-effective option than the TCAs. Furthermore, there is evidence that the emerging clinical differences between SSRIs may translate into significantly different economic outcomes within the group.

Sign in / Sign up

Export Citation Format

Share Document